A New Modality In Dyslipidemia Treatment: Antisense Oligonucleotide Therapy

A New Modality in Dyslipidemia Treatment: Antisense Oligonucleotide Therapy

JLA: Journal of Lipid and Atherosclerosis

Antisense Oligonucleotide Therapy for ALS

Shalini Andersson: Developing Oligonucleotides Into Therapies

Oligonucleotide Therapeutics Society

Spline-Switching Antisense Oligonucleotides for the Treatment of Disease (Michelle Hastings, PhD)

Houston Methodist DeBakey CV Education

New Therapeutic Approaches to the Treatment of Dyslipidemia 1: ApoC-III and ANGPTL3

JLA: Journal of Lipid and Atherosclerosis

Newly Approved Lipid-Lowering Therapies: The Top 5 Things to Know

Professor Robert A Hegele - The new genetics & therapies of dyslipidemias

At the Limits - Leading Medical Education

Sponsored webinar | Use of Atherosclerosis Quantification w/ Med, Diet, Activity, Edu for Prevention

Society of Cardiovascular Computed Tomography

Treating Dyslipidemia in 2020: Molds, Monoclonals, and mRNA Silencing

Yale Cardiovascular Medicine Grand Rounds

New Guidelines in Dyslipidemia

Southern Medical Association

2-9-2023 - Updates on Lipid Management: New Tools in the New Era

WashU Med Department of Medicine

PCSK9 Antibodies for Dyslipidemia: Efficacy, Safety, and Non-Lipid Effects

Lipid Management, Statins and New Therapies

Dr. Anas Abu Hazeem : Familial Hyperlipidemia in Children Diagnosis and Management

MCO Healthcare Conferences

New biology and therapeutic targets for dyslipidemia and atherosclerosis inspired by human genetics

Coverage of Statins/Nonstatins in Lipid Management

3.09.23 Grand Rounds: Treatment of Lipids in 2023: Where are we now and where are we going?: Trea...

Houston Methodist DeBakey CV Education

Driving LDL-C to target: Novel lipid therapies - Inclisiran

Health Innovation North West Coast

New Drug Shows Promise in Lowering Cholesterol Levels: A Game Changer? MK-0616

Dr. Constantine

LipiDiDiet: Evidence-based multi-nutrient intervention for prodromal Alzheimer’s disease